US Stock Movement | Replimune Rises Another 12% in Pre-market as Late-stage Melanoma Drug Application Sees Breakthrough

Golden Ten Data June 1｜Last Friday (May 29), Replimune (REPL.US) soared 85.68%, and today it continues to rise by 12.54% in pre-market trading, reaching $9.78. In the latest news, Replimune stated in a declaration that it has "agreed on a path forward" with the U.S. Food and Drug Administration (FDA) and will resubmit its application for its late-stage melanoma treatment drug, with the FDA promising to treat this review as an "urgent matter." Previously, in April this year, the FDA rejected Replimune's combination therapy for late-stage melanoma for the second time.